文献速递白血病

癌症基因突变累积与慢性髓性白血病不良结局相关

Mutation accumulation in cancer genes relates to nonoptimal outcome in chronic myeloid leukemia.
PubMed 文献 · Blood Adv · 2020-01-01

该研究对59例CML患者进行基因谱和转录组分析,发现BP期反复出现ABL1、ASXL1、RUNX1和BCOR体细胞突变,突变特征类似AML;诊断时和随访中非最优应答者的非沉默突变数多于最优应答者,提示突变负荷与不良结局相关。

要点

  • BP期常见ABL1、ASXL1、RUNX1和BCOR反复突变,突变特征类似AML。
  • 非最优应答者在诊断时和随访中非沉默突变数均多于最优应答者。
  • RNA测序在7例BP样本中的6例检出BCR-ABL1以外的癌症相关融合基因。

核心结论

  • CML患者癌症基因体细胞突变累积与疾病进展及非最优治疗结局相关。

研究设计与样本

  • 对59例CML患者进行基因谱分析(85份样本)和转录组分析(12份样本)。

主要发现

  • BP期检出ABL1(37%)、ASXL1(26%)、RUNX1(16%)和BCOR(16%)反复体细胞突变。
  • BP期突变特征与急性髓系白血病(AML)相似。
  • 非最优应答者诊断时和随访中非沉默突变数均多于最优应答者。
  • RNA测序在7例BP样本中的6例检出BCR-ABL1以外的癌症相关融合基因。

临床怎么用

  • 遗传数据可用于CML个体化医疗管理。
  • 表达改变涉及的机制和通路可作为CML管理的潜在靶点。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Chronic myeloid leukemia (CML) is a myeloproliferative neoplasm accounting for ∼15% of all leukemia. Progress of the disease from an indolent chronic phase to the more aggressive accelerated phase or blast phase (BP) occurs in a minority of cases and is associated with an accumulation of somatic mutations. We performed genetic profiling of 85 samples and transcriptome profiling of 12 samples from 59 CML patients. We identified recurrent somatic mutations in ABL1 (37%), ASXL1 (26%), RUNX1 (16%), and BCOR (16%) in the BP and observed that mutation signatures in the BP resembled those of acute myeloid leukemia (AML). We found that mutation load differed between the indolent and aggressive phases and that nonoptimal responders had more nonsilent mutations than did optimal responders at the time of diagnosis, as well as in follow-up. Using RNA sequencing, we identified other than BCR-ABL1 cancer-associated hybrid genes in 6 of the 7 BP samples. Uncovered expression alterations were in turn associated with mechanisms and pathways that could be targeted in CML management and by which somatic alterations may emerge in CML. Last, we showed the value of genetic data in CML management in a personalized medicine setting.

来源:Blood Adv,查看原文。版权归原作者所有。

引用

  1. Adnan Awad S, Kankainen M, Ojala T, et al. Mutation accumulation in cancer genes relates to nonoptimal outcome in chronic myeloid leukemia. Blood Adv. 2020. PMID: 32045476. doi:10.1182/bloodadvances.2019000943

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。